

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Koethe, JR; Heimburger, DC; PrayGod, G; Filteau, S (2016) From Wasting to Obesity: The Contribution of Nutritional Status to Immune Activation in HIV Infection. *The Journal of infectious diseases*, 214 Suppl 2. S75-82. ISSN 0022-1899 DOI: <https://doi.org/10.1093/infdis/jiw286>

Downloaded from: <http://researchonline.lshtm.ac.uk/2873501/>

DOI: [10.1093/infdis/jiw286](https://doi.org/10.1093/infdis/jiw286)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

Title: From Wasting to Obesity, the Contribution of Nutritional Status to Immune Activation in HIV Infection

Authors:

John R. Koethe MD, MS^{1,2}
Douglas C. Heimbürger, MD^{2,3}
George PrayGod, MD⁴
Suzanne Filteau, PhD⁵

Affiliations:

¹Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
² Vanderbilt Institute for Global Health, Nashville, TN, USA
³ Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
⁴ Mwanza Research Centre, National Institute for Medical Research, Mwanza, Tanzania
⁵ Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK

Running Head: Nutrition and Immune Activation in HIV

Word Count: 4905

Abstract word count: 150

Tables: 1

Figures: 1

Corresponding author:

John R. Koethe MD, MS
Assistant Professor of Medicine
Division of Infectious Diseases
Vanderbilt University Medical Center
A2200-MCN
1161 21st Avenue South
Nashville, TN 37232-2582
office: (615) 322-2035
fax: (615) 343-6160
Email: john.r.koethe@vanderbilt.edu

Funding: This manuscript was supported by grant K23AI100700 from the National Institutes of Health (NIH)

Conflicts of Interest: No authors report a conflict of interest

Abstract

The impact of HIV infection on innate and adaptive immune activation occurs in the context of host factors which serve to augment or dampen the physiologic response to the virus. Nutritional status, and in particular body composition, affects innate immune activation through a range of conditions including the loss of mucosal barrier protections and microbiome dysbiosis in malnutrition to the pro-inflammatory contribution of adipocytes and stromal vascular cells in obesity. Similarly, T cell activation, proliferation, and cytokine expression are reduced in the setting of malnutrition and increased in obesity, potentially due to adipokine regulatory mechanisms restraining energy-avid adaptive immunity in times of starvation and exerting a paradoxical effect in overnutrition. The response to HIV infection is situated within these complex interactions between host nutritional health and immunologic function, which contribute to the varied phenotypes of immune activation among HIV patients across a spectrum from malnutrition to obesity.

Key words: HIV, malnutrition, adipose tissue, obesity, inflammation, immune activation

1 **Introduction**

2 Following the introduction of effective antiretroviral therapy (ART) in resource-rich, developed
3 countries, the incidence of HIV-associated wasting in advanced disease has declined while the
4 proportion of overweight and obese HIV-infected individuals on long-term treatment has steadily risen
5 [1, 2]. In contrast, due to the geographic overlap of high HIV prevalence and chronic food insecurity,
6 new infections frequently occur against a backdrop of chronically insufficient macronutrient intake
7 (hereafter referred to as malnutrition) [3]. Host nutritional status affects innate immune activation
8 through a variety of mechanisms from altered mucosal barrier defenses and microbiome in malnutrition
9 to pro-inflammatory cytokine expression by stromal vascular cells and hypertrophied adipocytes in
10 obesity. Similarly, nutritional status modulates T cell activation, proliferation, and function, in part via
11 endocrine mechanisms thought to act on T cell surface receptors. Here, we review the interaction of
12 nutrition and the immune response to HIV across the spectrum of nutritional status ranging from
13 malnutrition to obesity (summarized in the Figure).

14

15 **Part 1: HIV and Malnutrition in Resource-Rich and Resource-Limited Contexts**

16 The young, emaciated patient with advanced AIDS is an enduring image of the early HIV epidemic, and
17 can unfortunately still be found with alarming frequency in many resource-limited settings where HIV
18 testing and treatment have not become universally available or accepted. However, a low body mass
19 index (BMI, a marker of generalized malnutrition) in the setting of HIV infection should be divided into
20 two frequently overlapping phenotypes. The first, cachexia, is a wasting phenotype characterized by a
21 dangerous cycle involving profound loss of adaptive immune system protection (i.e., CD4+ T cell
22 depletion), increased basal metabolic rate (due in part to a persistent inflammatory response), and
23 increased protein catabolism with accelerates the loss of lean body mass [4-10]. The second phenotype
24 arises from the simultaneous presence of clinical malnutrition due to insufficient caloric intake and

25 concomitant HIV infection in varying stages of immunosuppression. Global surveys estimate that over
26 800 million individuals have chronically insufficient caloric intake, with the highest prevalence in sub-
27 Saharan Africa and Southern Asia [11]. The prevalence of low BMI can be substantial in African HIV
28 patient populations; in a study of HIV-infected adults at clinics across Lusaka, the capitol of Zambia, one-
29 third were malnourished (BMI <18.5 kg/m²) at the time of ART initiation [12]. Frequently these
30 phenotypes overlap. In resource-rich settings progressive weight loss with untreated HIV leads to low
31 BMI and its associated organ system dysfunction and immune deficits, while in resource-limited settings
32 the immune deficits accompanying a low BMI are exacerbated by the acquisition of HIV infection.

33

34 Malnutrition, enteropathy and microbial translocation

35 The combined effects of environmental factors, nutrient deficits, and HIV infection on gastrointestinal
36 mucosal barrier defenses and microbiome composition (discussed below) contribute to increased
37 translocation of microbes and microbial proteins into the bowel wall and circulation in malnourished,
38 HIV-infected individuals [13-16]. Microbial translocation, as measured by circulating lipopolysaccharide
39 (LPS; a component of the bacterial cell wall), anti-endotoxin IgM and IgG antibodies, soluble CD14, and
40 other biomarkers is associated with accelerated HIV disease progression and a higher risk of mortality in
41 untreated HIV infection [17, 18], though the prognostic value of these biomarkers is less clear after ART
42 initiation [19, 20]. The loss of barrier defenses against microbial translocation in HIV infection also has
43 consequences for adaptive immune activation. In Italian HIV patients, serum LPS levels predicted disease
44 progression independently of age, CD4+ T-cell count, viral load, or duration of infection, and higher
45 circulating LPS levels after ART initiation were associated with greater CD4+ and CD8+ T cell activation
46 and poor CD4+ T cell recovery [17, 21].

47

48 Malnutrition enteropathy is characterized by bowel wall edema, reduced nutrient absorption and bowel
49 transit time, reduced secretory IgA production, and changes in mucosal surface morphology resulting in
50 villous blunting, increased permeability, and local inflammation [22, 23]. Environmental enteropathy,
51 thought to result from a combination of recurrent, transient infections with pathogenic bacteria and
52 altered intestinal microbiota, is common in tropical regions with poor sanitation and is also
53 characterized by villous blunting, reduced nutrient absorption, and accelerated bowel transit [16, 24-
54 26]. Lastly, HIV enteropathy is characterized by mucosal T cell depletion in conjunction with impaired
55 cellular tight junctions between epithelial cells [27-29]. The ensuing inflammatory response produces
56 villous changes similar to malnutrition enteropathy, which reduces nutrient absorption [30, 31]. In
57 resource-limited settings, the gastrointestinal system of malnourished HIV-infected individuals can be
58 affected by all three conditions simultaneously, and treatment of one condition (e.g., with ART
59 initiation) may not reduce inflammation and microbial translocation due to concomitant conditions.

60
61 Impaired gastrointestinal mucosal integrity and microbial translocation do not appear to be present
62 during acute HIV infection, and the temporal course of systemic inflammation attributed to microbial
63 translocation does not correspond entirely with markers of mucosal integrity or damage [15, 32].
64 Despite the initiation of ART and plasma viral suppression, defects in junctional complex expression, the
65 presence of bacterial products in the lamina propria, and reduced IL-17 and IL-22 producing cells persist
66 in treated HIV infection [28, 33], and even the early initiation of ART shortly after infection does not fully
67 normalize gastrointestinal mucosal dysfunction markers [34]. These findings suggest the changes in
68 mucosal integrity accompanying HIV infection involve permanent changes in gastrointestinal cellular
69 function, including the loss of IL-17 and IL-22 producing cells and altered epithelial gene expression,
70 which require time to emerge. While most studies of microbial translocation and innate immune

71 activation in HIV infection are from developed countries, similar findings are reported from resource-
72 limited settings [13, 14].

73

74 Malnutrition, HIV, and the microbiome

75 The centrality of the human gastrointestinal microbiome to the maintenance of host energy
76 homeostasis and metabolism was recognized decades ago, but more recent evidence points to an
77 important role modulating mucosal and systemic immune activity [35-37]. The human microbiome is
78 composed of an estimated 10^{14} microbes, comprising approximately 1000 species that include archaea,
79 bacteria and eukaryotes, but predominantly constituted by the five bacterial phyla of *Firmicutes*,
80 *Bacteroidetes*, *Actinobacteria*, *Proteobacteria* and *Verrucomicrobia* [38]. Quantitation of the relative
81 proportions of each phyla, and more specific taxonomic ranks, have identified consistent phenotypes
82 present in the setting of HIV infection, malnutrition, and states of persistent systemic inflammation and
83 adaptive immune activation.

84

85 An altered gastrointestinal microbiome appears to occur early in the course of HIV-infection and may
86 contribute to, or is at least correlated with, mucosal inflammatory activity, mucosal CD4+ T cell
87 depletion, and peripheral CD8+ T cell activation [39-41]. The microbiome alterations, and the
88 accompanying local and systemic immune effects, persist following the early stages of infection and do
89 not revert with ART treatment, possibly due to a persistent presence of HIV virus at the mucosal surface
90 or the lasting depletion of gastrointestinal CD4+ T cells and other immune effectors despite effective
91 suppression of plasma viremia [42, 43].

92

93 In a study of rectosigmoid biopsies from HIV-infected subjects not yet on ART, ART-treated subjects, and
94 HIV-negative controls, those with untreated HIV were found to have a marked dysbiosis of mucosal-

95 adherent bacteria characterized by increased *Proteobacteria* and reduced *Bacteroidetes*, which was
96 accompanied by increased mucosal CD4+ and CD8+ T cell activation, increased circulating CD8+ T cell
97 activation, and, among ART-treated participants, increased circulating IL-6 [44]. In particular, the
98 mucosal community was enriched for *Proteobacteria* genera including *Salmonella*, *Escherichia*, *Serratia*,
99 *Shigella*, and *Klebsiella* species, all of which can act as pro-inflammatory pathobionts. A similar shift in
100 gastrointestinal microbiome was seen in a subsequent study of colon biopsies of untreated HIV-infected
101 persons, which found increased *Proteobacteria*, reduced *Firmicutes*, and alterations in the relative
102 composition of the *Bacteroidetes* phylum compared to HIV-negative controls. Furthermore, the HIV-
103 associated changes in *Bacteroidetes* members, primarily an increase in *Prevotella*, were associated with
104 both mucosal and circulating CD4+ and CD8+ T cell activation [45]. Similar associations between
105 microbiome composition and systemic immune activation were observed in the fecal microbiome,
106 including a potentially a potentially beneficial effect of fecal *Lactobacillales* (phylum *Firmicutes*) to
107 promote circulating CD4+ T cell recovery and lower CD8+ T cell activation on ART [46, 47].

108
109 The preponderance of studies of HIV-negative, malnutrition-associated microbiome alterations enrolled
110 children rather than adults, but despite this limitation the observed commonalities with HIV-associated
111 gastrointestinal dysbiosis bear consideration. A link between kwashiorkor and a predominance of
112 *Staphylococcus aureus* and coliform bacteria of the phylum *Proteobacteria* in gastric juice and rectal
113 swabs was identified as early as 1958 [48]. Later studies of malnourished children and well-nourished
114 controls in Bangladesh found poor nutritional status was associated with enrichment of *Proteobacteria*,
115 including a 174-fold and nine-fold increase in *Klebsiella* and *Escherichia* respectively, and depletion of
116 *Bacteroidetes* [49]. In Indian children, nutritional status was negatively correlated with the proportion of
117 *Proteobacteria* (including *Escherichia*, *Shigella*, and *Enterobacter*) and positively correlated with the
118 proportion of anaerobic *Firmicutes* (including *Roseburia*, *Faecalibacterium*, and *Butyrivibrio*) [50]. This

119 pattern of enriched *Proteobacteria* and depleted *Bacteroidetes* and *Firmicutes* accompanying
120 malnutrition has also been observed in other case-control pediatric studies [51, 52].

121
122 At the phylum level, malnutrition is accompanied by gastrointestinal microbiome alterations similar to
123 those observed in untreated and ART-treated HIV-infected persons. While additional studies are needed
124 to confirm the dysbiosis observed in underweight children is also present in malnourished adults, it
125 seems reasonable to assume that adult malnutrition is accompanied by some degree of enrichment of
126 *Proteobacteria* and a depletion of *Bacteroidetes* and *Firmicutes*. To explore this further, we propose two
127 areas as research priorities: first, to investigate commonalities in mucosal immune dysfunction leading
128 to similar dysbiosis phenotypes in HIV infection and malnutrition; second, to determine the extent to
129 which a high degree of persistent immune activation in malnourished, HIV-infected individuals can be
130 attributed to compounding or synergistic effects of HIV and nutritional factors on the gastrointestinal
131 microbiome.

132
133 Food insecurity

134 Food insecurity, or a lack of consistent access to a sufficient quantity of affordable, nutritious food, is
135 associated with a higher likelihood of viral non-suppression in HIV-infected persons, with resultant
136 effects on disease progression and immune activation [53, 54]. In the United States and Europe, food
137 insecurity is more common among HIV patients with substance abuse, mental illness, and those living in
138 poverty, while in resource-limited settings food insecurity is often endemic in areas with high HIV
139 prevalence [55-57]. Food insecurity, and the frequently attendant economic privations, have adverse
140 effects on clinic attendance, obtaining medication refills, and taking ART at the frequency and dosages
141 prescribed, all of which lead to loss of virologic suppression, increased inflammation and cellular
142 immune activation, and higher likelihood of ART regimen failure and resistance [58-60]. Food assistance

143 may have a role in incentivizing patients to attend clinic visits and collect medications as scheduled [57,
144 61, 62].

145

146 A second aspect of food insecurity and immune activation is dietary quality, particularly in resource-
147 limited settings where HIV-infected individuals may be reliant on carbohydrate-rich staple foods (e.g.,
148 ground maize) with a high glycemic index. A recent systematic review of glycemic index and glycemic
149 load dietary intervention studies suggests high carbohydrate staple foods increase IL-6, CRP, and other
150 inflammation biomarkers [63], which may present an opportunity for properly-constituted food
151 assistance to reduce chronic immune activation in addition to improving clinic attendance and ART
152 adherence.

153

154 Malnutrition and T cell function

155 While there is a paucity of data from HIV-infected individuals, malnutrition is associated with broad
156 suppression of antigen-specific immunity, including reduced T cell output, maturation, proliferation, and
157 cytokine expression. The preponderance of these studies, by far, are in children or adolescents <18
158 years old and are summarized in a recent systematic review [64]; the findings should be extrapolated to
159 adults with some caution. Compared to the well-nourished, malnutrition is associated with reduced T
160 cell proliferative responses, reduced T cell expression of activation and memory surface markers [65,
161 66], and greater T_H2 polarization with concomitant decreased T_H1 cell IFN- γ and IL-2 production [66, 67].
162 Malnutrition is also accompanied by a lower likelihood of skin test conversion after Bacillus Calmette–
163 Guérin vaccination and reduced dermal delayed type hypersensitivity responses to *Candida*,
164 phytohemagglutinin and other common recall antigens [68]. Lastly, while total IgG and other antibody
165 levels were comparable between malnourished and well-nourished subjects in most prior studies,
166 reduced seroconversion rates or antibody titers were reported after typhoid, diphtheria, tetanus,

167 hepatitis B, measles and other vaccinations in severe malnutrition, though this does not appear to be as
168 uniform a finding for moderate and mild malnutrition [64]. While these deficits likely impair an efficient
169 response to pathogens, it is important to note the changes appear reversible and nutritional
170 rehabilitation of malnourished individuals is associated with an improvement in adaptive lymphocyte
171 proliferative responses, chemotaxis, and cytokine production [69].

172

173 **Part 2: Adipose Tissue and Immune Activation in Comorbid HIV and Obesity**

174 Adipose tissue represents one of the largest organs in the body and comprises a range of cell types with
175 diverse energy storage, metabolic regulation, neuroendocrine, and immunologic functions. HIV infection
176 and ART treatment cause alterations to adipose tissue distribution and biology with broad effects on
177 cytokine and hormone expression, lipid storage, and the composition of adipose-resident immune cell
178 populations. The resultant changes have important consequences for innate and adaptive immune
179 responses and chronic immune activation.

180

181 *Obesity prevalence in the HIV population*

182 The proportion of overweight and obese individuals in high- and middle-income countries has increased
183 steadily over the past three decades, affecting all race/ethnicity, sex, and age groups to varying degrees,
184 and more recently obesity rates have increased in low-income countries [70]. More than one-third of
185 adults in the United States are overweight (BMI 25-29.9 kg/m²) and a similar proportion are obese (BMI
186 >30 kg/m²) [71]. Obesity is also becoming more prevalent in the HIV population. In an analysis of over
187 14,000 HIV-infected persons in the United States and Canada, the percentage of patients who were
188 obese at ART initiation increased from 9% to 18% between 1998 and 2010, and 22% of individuals with
189 normal BMI (18.5-25 kg/m²) at treatment initiation had become overweight after three years of ART,
190 and 18% of those overweight at initiation had become obese. Compared to age-matched National

191 Health-Nutrition Examination Survey (NHANES) controls from the general population, HIV-infected
192 white women had a higher BMI after 3 years of ART as compared to controls, while no difference in BMI
193 after 3 years of ART was observed for HIV-infected white men and non-white men and women
194 compared to controls [2].

195

196 HIV infection alters adipose tissue distribution and metabolic characteristics

197 Older ART agents, particularly the thymidine analogues zidovudine (AZT) and stavudine (d4T), were
198 associated with a high prevalence (up to 50% in some studies) of peripheral lipotrophy of the limbs,
199 face, and buttocks; lipohypertrophy of the visceral, cervical, and dorsocervical area (i.e., the “buffalo
200 hump”); or a combination of these changes [72, 73]. The accumulation of ectopic adipose tissue in a
201 variety of organs, particularly epicardial, hepatic, and muscle bundle fat infiltration, contributes to local
202 inflammation and end-organ disease [74-76]. Subcutaneous fat biopsies from individuals with HIV-
203 associated lipotrophy demonstrate reduced mitochondrial DNA (mtDNA) and structural changes
204 characterized by increased fibrosis, apoptosis, and formulation of lipogranulomas, while the adipocytes
205 demonstrate reduced expression of several transcription factors necessary for cellular differentiation
206 and fatty acid uptake, but higher TNF- α and IL-6 expression [77-81]. Taken together, these findings
207 indicate a shift to a pro-inflammatory, profibrotic, and dysregulated metabolic state within the fat tissue
208 of HIV patients. While the prevalence of lipodystrophy has declined with the introduction of newer ART
209 agents, the presence of HIV viral particles and latently HIV-infected, adipose-resident CD4+ T cells within
210 adipose tissue may still contribute to impaired lipid metabolism and storage [82, 83].

211

212 Obesity, HIV, and the microbiome

213 As discussed above in the sections on malnutrition, HIV-infection can be accompanied by a marked
214 dysbiosis of fecal and mucosal-adherent bacteria characterized by increased *Proteobacteria* and reduced

215 *Bacteroidetes* and *Firmicutes*, and these changes are associated with mucosal T cell activation,
216 circulating T cell activation, and serum markers of innate immune activation [44, 45]. Independent of
217 HIV infection, obesity is accompanied by characteristic changes in the gastrointestinal microbiome
218 characterized by lower levels of *Bacteroidetes* and proportionately higher levels of *Firmicutes* in several
219 studies [84-86], which are postulated to enhance dietary nutrient absorption [87]. In animal models,
220 stool characterized by this phylum-level shift was shown to ‘transmit’ obesity when inoculated into lean
221 animals [84], suggesting that alterations of the gastrointestinal microbiome by conditions such as HIV
222 infection could alter energy uptake and the metabolic balance. Colon biopsies of untreated, HIV-infected
223 persons show reduced *Firmicutes* but little change in *Bacteroidetes* at the phylum level compared to
224 HIV-negative controls (however, the relative composition of *Bacteroidetes* at the genus level did shift)
225 [45]. Based on prior animal and human studies, this alteration in the *Bacteroidetes* : *Firmicutes* ratio in
226 untreated HIV would appear to be protective against obesity. However, many patients gain weight after
227 ART initiation, particularly in the first 12 months, and the potential contribution of microbiome changes
228 after ART initiation to weight gain is one area for further study [2].

229

230 *Obesity is associated with increased serum inflammatory markers in HIV-infected persons*

231 As observed in the general population, serum levels of CRP are higher among HIV-infected adults with
232 greater adiposity [88-91]. In the Fat Redistribution and Metabolic Change in HIV Infection (FRAM)
233 cohort, each twofold increase in visceral adipose tissue was associated with 17% higher serum CRP,
234 while a similar increase in subcutaneous adipose tissue was associated with 21% higher levels [88].
235 Circulating levels of IL-6, TNF- α receptor 1, and macrophage inflammatory protein-1 α also rise in
236 proportion to fat mass in HIV-infected persons, likely due to greater expression from stromal vascular
237 cells and hypertrophied adipocytes [91, 92]. The enlargement of adipose tissue depots is primarily due
238 to adipocyte hypertrophy, rather than hyperplasia, and increases in adipocyte size result in

239 disproportionate increases in IL-6 and TNF- α expression [93-95]. It is estimated that adipose tissue-
240 derived IL-6 constitutes up to 35% of circulating levels in obese individuals and is a substantial
241 contributor to CRP production [96]. This raises the question of whether the reported association
242 between CRP or IL-6 levels and adverse health outcomes in studies of predominantly non-obese
243 populations should be extrapolated to obese HIV-infected individuals, as in the obese a higher
244 proportion of these biomarkers may emanate from adipose tissue as opposed to other sites of
245 inflammation [97-99].

246

247 Obesity and adipose tissue immune cell profiles

248 Immune cell infiltration of adipose tissue accompanies progressive weight gain and contributes to both
249 *in situ* and systemic inflammation. Adipose tissue from obese humans and animal models shows a
250 striking increase in CD8+ T cells and T_H1 and T_H17-polarized CD4+ cells, a decrease in T regulatory cells,
251 and an increase in M1-phenotype (TNF- α , IL-12, IL-23-producing) pro-inflammatory macrophages [100-
252 103]. CD8+ T cell infiltration into adipose tissue is an early and necessary step preceding M1-phenotype
253 macrophage recruitment in mice, and antibody-induced CD8+ T cell depletion results in reduced M1-
254 phenotype macrophage adipose tissue infiltration [100]. Adipocyte hypertrophy is associated with
255 increased production of macrophage chemotactic protein-1 and macrophage inflammatory protein-1 α ,
256 which promote macrophage infiltration, and increased IL-8, which promotes neutrophil chemotaxis
257 [104-106].

258

259 Recent studies highlight an important role for T_H17 cells, a subset of CD4+ effector T cells defined by
260 their production of IL-17, in promoting adipose tissue inflammation and metabolic disease [107, 108].
261 T_H17 cells are central contributors to the maintenance of mucosal barriers, pathogen clearance at the
262 mucosal surface, and the defense against fungi and extracellular bacteria [109, 110], but loss or

263 dysregulation of T_H17 cells is also implicated in the pathogenesis of autoimmune and inflammatory
264 conditions [111]. Adipose tissue CD4⁺ T cells in obese, insulin resistant persons are skewed toward a
265 T_H17 phenotype, and the tissue microenvironment is characterized by high levels of T_H17-promoting IL-
266 1 β and IL-6 in addition to the T_H17 markers RORC, IL-17, and IL-23R [107, 112]. M1-phenotype
267 macrophage cytokine expression promotes a cycle of progressive T_H17-polarization and inflammation,
268 with IL-1 β and IL-6 promoting the differentiation of T_H17 cells and IL-23 promoting their stabilization and
269 expansion [113, 114]. While circulating IL-17 levels are frequently low or undetectable, *in vitro* IL-17
270 inhibits skeletal muscle glucose uptake and hepatocyte insulin sensitivity [107]. A recent study describes
271 the role of ATP leakage into the extracellular space, a hallmark of pathologic cellular conditions such as
272 apoptosis, inflammation, or ischemia, in promoting a T_H17-polarizing milieu [115]. The addition of ATP to
273 visceral adipose tissue from metabolically healthy lean subjects enriched the tissue microenvironment
274 for IL-1 β , IL-6, and IL-17, and higher CD4⁺ T cell expression of a characteristic T_H17 cytokine signature
275 [112]. These studies suggest a central role for T_H17 CD4⁺ cells in propagating adipose tissue
276 inflammation, and further studies are needed to understand whether HIV status alters the distribution
277 and activity of adipose tissue T_H17-polarized cells in obesity.

278

279 Adipose tissue also serves as a reservoir of CD4⁺ T cells harboring latent HIV infection. A recent study
280 found a higher percentage of activated CD4⁺ and CD8⁺ T cells in adipose tissue from HIV-infected
281 subjects compared to HIV-negative controls, in addition to the unique presence of latently HIV-infected
282 memory CD4⁺ T cells [82, 116]. Furthermore, the median copy number of latent HIV DNA in
283 subcutaneous adipose tissue CD4⁺ T cells was slightly higher than the median copy number in circulating
284 CD4⁺ T cells, indicating adipose tissue serves as a significant reservoir for latent HIV infection [116].
285 Similar findings regarding a higher proportion of activated CD8⁺ and CD4⁺ T cells, and latently infected

286 memory CD4+ T cells, in both subcutaneous and visceral adipose tissue have been reported in simian
287 immunodeficiency virus-infected macaques compared to uninfected animals [116].

288

289 *Obesity and circulating T cell profiles in HIV-infected and HIV-negative persons*

290 Studies from the pre-ART era found a higher BMI was associated with slower disease progression and
291 CD4+ T cell decline [117-119]. However, it is unclear whether the delayed immunosuppression observed
292 among high BMI individuals was due to an effect of greater adiposity versus other factors such as fewer
293 secondary infections or micronutrient deficiencies. Recent studies in the combination ART era found a
294 higher BMI may promote more robust CD4+ T cell recovery on treatment [120, 121]. An analysis of over
295 14,000 HIV-infected adults in 13 multi-site cohorts found a higher time-updated BMI was significantly
296 associated with greater CD4+ cell count recovery on ART [122]. After 5 years of ART, the mean CD4+ cell
297 count for a hypothetical patient with a BMI of 30 kg/m² was 20% higher compared to a patient with a
298 BMI of 22 kg/m² (524 vs. 436 cells/μL), and 31% higher for a BMI of 40 kg/m² compared to 22 kg/m²
299 (572 vs. 436 cells/μL).

300

301 A minimum quantity of adipose tissue appears necessary to maintain normal-range lymphocyte subset
302 counts, but assessing the relationship between adiposity and peripheral T cell populations in the setting
303 of HIV infection is confounded by CD4+ T cell depletion, variations in immune recovery on ART, and the
304 effects of HIV-related immune activation. Thus, studies of HIV-negative individuals may be revealing in
305 this area. Overweight and obese HIV-negative women had higher CD4+ and total lymphocyte counts
306 compared to normal weight women in one study [123], while the expression of activation marker CD25
307 on CD3+ T cells was 3-fold higher in obese subjects compared to non-obese, and the ratio of T_H1 to T_H2
308 CD4+ lymphocytes was also significantly higher, in another study [124]. Similarly, an analysis of the
309 European CODAM cohort of HIV-negative individuals found greater waist circumference was associated

310 with higher circulating markers of adaptive immune activation (neopterin and soluble CD25) [125].
311 Taken together, these data suggest that, irrespective of HIV infection, higher fat stores are associated
312 with higher circulating CD4 T cell populations, greater T_H1 polarization, and expression of surface
313 markers of immune activation.

314

315 Adipose tissue hormones alter lymphocyte function

316 Adipokines are hormones produced by adipocytes which demonstrate a range of metabolic,
317 neuroendocrine, and immunomodulatory properties. Leptin, an adipokine encoded by the *ob* gene and
318 produced roughly in proportion to fat cell mass, was initially characterized as a regulator of appetite but
319 also appears to have a range of local and potentially systemic immune effects [126-128]. Leptin
320 independently induces expression of pro-inflammatory cytokines by macrophages and monocytes [129,
321 130], and acts directly on hepatocytes to promote CRP expression [131]. Mature CD4+ T cells express
322 the long isoform of the leptin receptor [132, 133], and leptin stimulates T cell proliferative responses *in*
323 *vitro*, polarizes naïve CD4+ T cell proliferation towards the T_H1 phenotype, and promotes a marked
324 increase in IFN- γ and other T_H1-type cytokines [133-137]. Leptin also enhances *in vitro* expression of
325 activation markers (CD69, CD25, and CD71) on both CD4+ and CD8+ T cells after antigen stimulation in a
326 dose-dependent manner [136, 138]. While the administration of physiologic quantities of recombinant
327 leptin to non-HIV-infected adults with acquired or congenital lipodystrophy increased peripheral CD4+
328 and CD8+ cell counts, two small trials in HIV-infected individuals have not shown a benefit to CD4+ cell
329 recovery on ART [139-142].

330

331 Therapeutic trials to reduce adiposity and immune activation in HIV-infected individuals

332 Trials of exercise and lifestyle modification have shown reductions in serum CRP, weight loss, and
333 improved cardiorespiratory fitness in HIV persons, though benefits for insulin sensitivity and fasting

334 glucose are less clear [143-146]. In morbidly obese HIV-infected persons, bariatric surgery appears to be
335 safe and does not affect viral suppression [147, 148].

336

337 The accumulation of visceral fat in HIV-infected individuals is accompanied by reductions in endogenous
338 circulating and stimulated growth hormone (GH) levels, a finding also observed in HIV-negative persons
339 with abdominal obesity and independent of age, BMI, and total body fat [149-151]. Inadequate GH
340 levels are associated with reduced bone mineralization, dyslipidemia (characterized by elevated
341 triglycerides and low HDL), elevated blood pressure, reduced vascular health, higher circulating CRP, and
342 a detrimental cycle of further accumulation of visceral adiposity with concomitant progressive
343 reductions in GH secretion [152-155]. Among HIV-infected persons, lower peak levels of GH are
344 associated with higher CRP levels, in addition to higher fasting glucose levels and triglycerides
345 independent of waist circumference [156].

346

347 Studies of GH replacement in persons with hypopituitarism demonstrated reductions in visceral
348 adiposity and inflammation, and improved lipid parameters and markers of vascular health, which
349 suggested possible benefits for HIV-infected persons with abdominal obesity [153, 157-159]. However,
350 while trials of recombinant human growth hormone (rhGH) in obese, HIV-infected persons have shown
351 reductions in visceral adipose tissue and hepatic fat [160-162], these benefits must be weighed against
352 the increased insulin resistance observed with rhGH treatment [161-164]. Furthermore, the beneficial
353 effects of GH supplementation on innate immune activation in persons with hypopituitarism are not as
354 evident in HIV-infected individuals. A multi-arm study of rhGH, rosiglitazone, combination rhGH and
355 rosiglitazone, and placebo found no significant difference in a range of serum inflammation biomarkers,
356 including CRP, IL-1, IL-6, TNF- α , and interferon gamma, between study arms after 12 weeks of treatment
357 [160].

358

359 Tesamorelin, a synthetic form of growth-hormone-releasing hormone (GHRH), is a FDA-approved
360 treatment to reduce abdominal fat in HIV-infected patients with lipodystrophy. Trials of Tesamorelin
361 demonstrate visceral and hepatic fat reductions, gains in lean body mass, and improved lipid profiles,
362 but without the increase in insulin resistance which limited the clinical utility of rhGH [165-167].
363 However, despite substantial reductions in visceral fat with Tesamorelin, it is notable that a 26-week
364 randomized trial did not demonstrate a significant effect on CRP levels, and more studies are needed to
365 characterize the effects of Tesamorelin on innate and cellular immune activation [168].

366

367 **Conclusion**

368 Persistent, chronic innate and adaptive immune activation have been implicated in the pathogenesis of
369 multiple comorbidities in HIV patients and impaired immune recovery on ART. While the etiology of this
370 heightened immune activation is multifactorial, the immunologic effects of HIV infection can be
371 amplified and modulated by host nutritional factors. At the intersection of these nutritional and
372 immunologic processes an opportunity may be present for interventions to mitigate the adverse effects
373 of both malnutrition and obesity on chronic immune activation and improve health outcomes in HIV-
374 infected individuals.

References

- 375
- 376 1. Hasse B, Iff M, Ledergerber B, et al. Obesity Trends and Body Mass Index Changes After Starting
377 Antiretroviral Treatment: The Swiss HIV Cohort Study. *Open Forum Infect Dis* **2014**; 1:ofu040.
- 378 2. Koethe JR, Jenkins CA, Lau B, et al. Rising Obesity Prevalence and Weight Gain Among Adults Starting
379 Antiretroviral Therapy in the United States and Canada. *AIDS Res Hum Retroviruses* **2016**; 32:50-8.
- 380 3. Koethe JR, Heimbürger DC. Nutritional aspects of HIV-associated wasting in sub-Saharan Africa. *Am J*
381 *Clin Nutr* **2010**; 91:1138S-1142S.
- 382 4. Kotler DP, Tierney AR, Wang J, Pierson RN, Jr. Magnitude of body-cell-mass depletion and the timing
383 of death from wasting in AIDS. *Am J Clin Nutr* **1989**; 50:444-7.
- 384 5. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency
385 virus infection. *N Engl J Med* **1995**; 333:83-8.
- 386 6. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure,
387 caloric intake, and short-term weight change in human immunodeficiency virus infection and the
388 acquired immunodeficiency syndrome. *Am J Clin Nutr* **1992**; 55:455-60.
- 389 7. Shevitz AH, Knox TA, Spiegelman D, Roubenoff R, Gorbach SL, Skolnik PR. Elevated resting energy
390 expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. *AIDS* **1999**;
391 13:1351-7.
- 392 8. Melchior JC, Raguin G, Boulier A, et al. Resting energy expenditure in human immunodeficiency virus-
393 infected patients: comparison between patients with and without secondary infections. *Am J Clin Nutr*
394 **1993**; 57:614-9.
- 395 9. Yarasheski KE, Zachwieja JJ, Gischler J, Crowley J, Horgan MM, Powderly WG. Increased plasma gln
396 and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. *Am J Physiol* **1998**;
397 275:E577-83.
- 398 10. Macallan DC, McNurlan MA, Milne E, Calder AG, Garlick PJ, Griffin GE. Whole-body protein turnover
399 from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. *Am J*
400 *Clin Nutr* **1995**; 61:818-26.
- 401 11. Food and Agricultural Organization of the United Nations. The State of Food Insecurity in the World
402 2014. Rome: FAO, **2014**. Available at: <http://www.fao.org/publications/sofi/2014/en/>.
- 403 12. Koethe JR, Lukusa A, Giganti MJ, et al. Association between weight gain and clinical outcomes among
404 malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. *J Acquir Immune Defic Syndr*
405 **2010**; 53:507-13.

- 406 13. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in
407 HIV-1-infected South Africans receiving combination antiretroviral therapy. *J Infect Dis* **2010**; 202:723-
408 33.
- 409 14. Canipe A, Chidumayo T, Blevins M, et al. A 12 week longitudinal study of microbial translocation and
410 systemic inflammation in undernourished HIV-infected Zambians initiating antiretroviral therapy. *BMC*
411 *Infect Dis* **2014**; 14:521.
- 412 15. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune
413 activation in chronic HIV infection. *Nat Med* **2006**; 12:1365-71.
- 414 16. Prendergast A, Kelly P. Enteropathies in the developing world: neglected effects on global health. *Am*
415 *J Trop Med Hyg* **2012**; 86:756-63.
- 416 17. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts disease progression of
417 HIV-infected antiretroviral-naive patients with high CD4+ cell count. *AIDS* **2011**; 25:1385-1394.
- 418 18. Leon A, Leal L, Torres B, et al. Association of microbial translocation biomarkers with clinical
419 outcome in controllers HIV-infected patients. *AIDS* **2015**; 29:675-81.
- 420 19. Sandler NG, Wand H, Roque A, et al. Plasma Levels of Soluble CD14 Independently Predict Mortality
421 in HIV Infection. *J Infect Dis* **2011**; 203:780-790.
- 422 20. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Pre -cART Pro -inflammatory milieu, Microbial
423 Translocation (MT) and Risk of Disease Progression in HIV-infected Patients Starting Their First cART:
424 Data from the Icona Foundation Cohort. In: European AIDS Clinical Society (EACS), Barcelona; 2015.
425 **2015**.
- 426 21. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure
427 in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy.
428 *AIDS* **2008**; 22:2035-8.
- 429 22. Elia M, Goren A, Behrens R, Barber RW, Neale G. Effect of total starvation and very low calorie diets
430 on intestinal permeability in man. *Clin Sci (Lond)* **1987**; 73:205-10.
- 431 23. Welsh FK, Farmery SM, MacLennan K, et al. Gut barrier function in malnourished patients. *Gut* **1998**;
432 42:396-401.
- 433 24. Kelly P, Menzies I, Crane R, et al. Responses of small intestinal architecture and function over time to
434 environmental factors in a tropical population. *Am J Trop Med Hyg* **2004**; 70:412-9.
- 435 25. Veitch AM, Kelly P, Zulu IS, Segal I, Farthing MJ. Tropical enteropathy: a T-cell-mediated crypt
436 hyperplastic enteropathy. *Eur J Gastroenterol Hepatol* **2001**; 13:1175-81.
- 437 26. Dhaliwal W, Bajaj-Elliott M, Kelly P. Intestinal defensin gene expression in human populations. *Mol*
438 *Immunol* **2003**; 40:469-75.

- 439 27. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and
440 nonpathogenic lentiviral infections. *Blood* **2008**; 112:2826-35.
- 441 28. Nazli A, Chan O, Dobson-Belaire WN, et al. Exposure to HIV-1 directly impairs mucosal epithelial
442 barrier integrity allowing microbial translocation. *PLoS Pathog* **2010**; 6:e1000852.
- 443 29. Sankaran S, George MD, Reay E, et al. Rapid onset of intestinal epithelial barrier dysfunction in
444 primary human immunodeficiency virus infection is driven by an imbalance between immune response
445 and mucosal repair and regeneration. *J Virol* **2008**; 82:538-45.
- 446 30. Keating J, Bjarnason I, Somasundaram S, et al. Intestinal absorptive capacity, intestinal permeability
447 and jejunal histology in HIV and their relation to diarrhoea. *Gut* **1995**; 37:623-9.
- 448 31. Kapembwa MS, Fleming SC, Sewankambo N, et al. Altered small-intestinal permeability associated
449 with diarrhoea in human-immunodeficiency-virus-infected Caucasian and African subjects. *Clin Sci*
450 (Lond) **1991**; 81:327-34.
- 451 32. Chevalier MF, Petitjean G, Dunyach-Remy C, et al. The Th17/Treg ratio, IL-1RA and sCD14 levels in
452 primary HIV infection predict the T-cell activation set point in the absence of systemic microbial
453 translocation. *PLoS Pathog* **2013**; 9:e1003453.
- 454 33. Smith AJ, Schacker TW, Reilly CS, Haase AT. A role for syndecan-1 and claudin-2 in microbial
455 translocation during HIV-1 infection. *J Acquir Immune Defic Syndr* **2010**; 55:306-15.
- 456 34. Jenabian MA, El-Far M, Vyboh K, et al. Immunosuppressive Tryptophan Catabolism and Gut Mucosal
457 Dysfunction Following Early HIV Infection. *J Infect Dis* **2015**; 212:355-66.
- 458 35. Savage DC. Microbial ecology of the gastrointestinal tract. *Annu Rev Microbiol* **1977**; 31:107-33.
- 459 36. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human
460 intestine. *Science* **2005**; 307:1915-20.
- 461 37. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune
462 system. *Science* **2012**; 336:1268-73.
- 463 38. Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. *Nat Rev*
464 *Microbiol* **2016**; 14:20-32.
- 465 39. Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role
466 for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. *J Clin*
467 *Microbiol* **2008**; 46:757-8.
- 468 40. Ellis CL, Ma ZM, Mann SK, et al. Molecular characterization of stool microbiota in HIV-infected
469 subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with
470 immune activation. *J Acquir Immune Defic Syndr* **2011**; 57:363-70.

- 471 41. Merlini E, Bai F, Bellistri GM, Tincati C, d'Arminio Monforte A, Marchetti G. Evidence for polymicrobial
472 flora translocating in peripheral blood of HIV-infected patients with poor immune response to
473 antiretroviral therapy. *PLoS One* **2011**; 6:e18580.
- 474 42. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal
475 microbiome and immune activation parameters in HIV infected subjects. *PLoS Pathog* **2014**;
476 10:e1003829.
- 477 43. Voigt RM, Keshavarzian A, Losurdo J, et al. HIV-associated mucosal gene expression: region-specific
478 alterations. *AIDS* **2015**; 29:537-46.
- 479 44. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV
480 disease progression and tryptophan catabolism. *Sci Transl Med* **2013**; 5:193ra91.
- 481 45. Dillon SM, Lee EJ, Kotter CV, et al. An altered intestinal mucosal microbiome in HIV-1 infection is
482 associated with mucosal and systemic immune activation and endotoxemia. *Mucosal Immunol* **2014**;
483 7:983-94.
- 484 46. Perez-Santiago J, Gianella S, Massanella M, et al. Gut Lactobacillales are associated with higher CD4
485 and less microbial translocation during HIV infection. *AIDS* **2013**; 27:1921-31.
- 486 47. Dinh DM, Volpe GE, Duffalo C, et al. Intestinal microbiota, microbial translocation, and systemic
487 inflammation in chronic HIV infection. *J Infect Dis* **2015**; 211:19-27.
- 488 48. Smythe PM. Changes in intestinal bacterial flora and role of infection in Kwashiorkor. *Lancet* **1978**;
489 2:724-727.
- 490 49. Monira S, Nakamura S, Gotoh K, et al. Gut microbiota of healthy and malnourished children in
491 bangladesh. *Front Microbiol* **2011**; 2:228.
- 492 50. Ghosh TS, Gupta SS, Bhattacharya T, et al. Gut microbiomes of Indian children of varying nutritional
493 status. *PLoS One* **2014**; 9:e95547.

Table: Summary Points on Nutrition and Immune Activation

- Enteropathy due to a confluence of environmental factors, nutrition deficits, and viral effects impairs mucosal barrier integrity and immune defenses, and contributes to both innate and cellular immune activation in malnourished HIV-infected persons.
- A gastrointestinal dysbiosis, characterized by increased *Proteobacteria* and reduced or altered *Bacteroidetes* and *Firmicutes*, is present in HIV patients, and these changes are accompanied by increased mucosal and circulating T cell activation and systemic inflammation. Similar phylum-level changes occur in malnutrition, but the microbiome consequences of comorbid HIV infection and malnutrition are unknown.
- Malnutrition is associated with reduced T cell proliferative responses, reduced T cell expression of activation and memory surface markers, greater type-2 T helper cell (T_H2) polarization, and decreased T_H1 cell interferon- γ and interleukin-2 production, which compound HIV-related immunodeficiency and impair clearance or control of secondary infections.
- Adipocytes constitutively express interleukin-6, tumor necrosis factor- α , and other cytokines, and obese HIV-infected persons have substantially higher circulating levels of inflammation biomarkers. Because these cytokines derive from adipocytes as opposed to other tissues (e.g., blood vessels), obesity may confound previously reported associations between inflammation and health outcomes in HIV-infected persons.
- A higher BMI is associated with more robust CD4+ recovery on antiretroviral therapy, and obesity in is associated with higher circulating T cell counts, increased T cell activation, and CD4+ cell T_H1 polarization in studies of HIV-negative individuals.

- CD4+ T cells express a receptor for leptin, an adipokine produced by adipocytes, which may have an endocrine function modulating T cell proliferation, activation, and T-helper cell polarization in states of both malnutrition and obesity.
- Clinical trials of growth-hormone-releasing hormone (GHRH) have shown a beneficial effect for reducing visceral and hepatic fat without the added insulin resistance observed in studies of recombinant growth hormone. However, the effect of GHRH on innate and cellular immune activation is still unclear.

Malnutrition and Obesity-related Factors Potentially Affecting Chronic Immune Activation in HIV Infection

Innate immunity:

- Reduced GI mucosal integrity
- Higher microbial translocation
- Villous blunting and local inflammation
- Lower secretory IgA
- Lower eosinophils and NK cells

Adaptive immunity:

- Lower total lymphocytes
- Reduced T cell proliferative response
- Higher T_H2-type CD4+ cell polarization
- Lower T_H1 cell IL-2 and INF- γ expression
- Impaired delayed hypersensitivity response

Potential interventions:

- Food assistance / macronutrient supplements
- Livelihood support / cash transfers
- Clean water & sanitation programs to reduce environmental pathogens
- Expanded HIV testing and earlier treatment



Innate immunity:

- Higher circulating IL-6 and other cytokines produced by adipocytes
- M1 inflammatory macrophage and T_H17 CD4+ T cell polarization in adipose tissue
- Leptin (adipokine) promotes macrophage TNF- α , IL-6 and IL-12 expression

Adaptive immunity:

- More robust CD4+ cell recovery on antiretroviral therapy at higher BMI
- Increased peripheral T cells, T cell activation, and T_H1-type CD4+ cell polarization
- Leptin (an adipokine produced by adipocytes) promotes CD4+ T cell proliferation and T_H1 polarization *in vitro*

Potential Interventions:

- Weight loss and exercise programs
- Gastric bypass
- Growth-hormone-releasing hormone (Tesamorelin)